Empower Clinics Inc., - CEO, Steven McAuley
CEO, Steven McAuley
Source: Proactive Investors
  • Cannabis company Empower Clinics (CSE:CBDT) has launched nation-wide telemedicine services, through its Sun Valley Health division
  • The company will begin by offering physicians access to its new digital health platform 
  • Telemedicine will be available both in-clinic, and virtually, through secure video, on browser, and via mobile app
  • Empower has a base of 165,000 patients, and may reach an additional 329 million people in its US roll-out
  • Empower’s share price was trading for 7 cents per share on Thursday’s market close

Cannabis company Empower Clinics (CSE:CBDT) has launched nation-wide telemedicine services, through its Sun Valley Health division.

Sun Valley is moving forward with its digital health initiatives, such as safe and secure physician-patient interactions. The company will begin by offering physicians access to its new digital health platform. Doctors will use the platform for a variety of physician-based consultations.

Empower’s telemedicine services will be available both in-clinic, and virtually, through secure video, on browsers, and via mobile app. Specifically, the early initiatives will combine in-clinic virtual kiosk-based physician visits, and full telemedicine virtual consultations. The full telemedicine services will depend on patient ability. 

Telemedicine and telehealth have experienced a sudden and extraordinary boom with the advent of the recent COVID-19 pandemic. As the virus keeps people in isolation, the need for remote medical visits has become a necessity. 

Empower Clinics’ CEO, Steven McAuley, commented on how the company and industry is responding to the global health crisis.

“The COVID-19 pandemic has forever changed the interaction between physicians and patients. The situation requires immediate advancement in technology solutions, that offer safe interactions to a vast array of patient needs.

Our team are fast-tracking progressive technology, products, and service options, to support the needs of our patients, staff, and community,” he said. 

Empower currently has a base of 165,000 patients. However, as the company begins a nation-wide rollout in the US, it could potentially reach an additional 329 million people. 

Based on recommendations from the Centres for Disease Control and Prevention (CDC), Empower has made changes to clinic operations and patient management. These changes are in line with the CDC’s specific guidance for healthcare facilities. 

Empower’s share price was trading for 7 cents per share on Thursday’s market close.

More From The Market Herald

The Market Herald’s Weekly Cannabis Report – Dec. 8, 2023

Investors in the cannabis industry have had their eyes on Canopy Growth stock, considering its potential for growth and profitability.

Buzz on the Bullboards: Who’s taking off and who’s grounded

As everyone races toward the finish line, let’s take a look at some of the stocks that are standing out from the rest.

Cannara reports record growth and profitability in Q4 2023

Cannabis producer Cannara Biotech Inc. (TSXV:LOVE) reported record growth and profitability in its Q4 and 2023 fiscal year results.

Will Canopy Growth stock recover?

Cannabis Investors have had their eyes on Canopy Growth (TSX:WEED) stock, considering its potential for growth and profitability.